AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04668872 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PET/CT
Description: Following 90Y TARE, participants will receive a PET/CT or PET/MRI scan to measure the dose administered to the target tumor(s) and uninvolved hepatic parenchyma.
Study NCT01632956 — intervention group
Intervention type: BEHAVIORAL
Intervention: virtual support group
Description: Each support group will consist of 12 sessions. Thirty-two breast cancer patients of Chinese descent will be recruited to participate in the support groups (16 in the inperson groups and 16 in the virtual groups).
Study NCT04136990 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Isolated ACL reconstruction
Description: Isolated ACL reconstruction using the bone-patellar tendon autograft.
Study NCT04136990 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL + LEAT reconstruction
Description: ACL reconstruction using the bone-patella-tendon-bone autograft combined with LEAT using the mini Lemaire technique.
Study NCT01756599 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples
Study NCT04668872 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PET/MRI
Description: Following 90Y TARE, participants will receive a PET/CT or PET/MRI scan to measure the dose administered to the target tumor(s) and uninvolved hepatic parenchyma.
Study NCT04322097 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lingual Muscle Stimulation
Description: Tongue protrudor muscles will be stimulated
Study NCT03664882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine M016455
Description: Pharmaceutical form: tablet Route of administration: oral
Study NCT03664882 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: tablet Route of administration: oral
Study NCT04912947 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Immusystem
Description: Dietary supplement containing: Piceid, Glycine, Glutamine, Acetylcysteine, Zinc and Vitamin B6
Study NCT04912947 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin placebo capsule
Study NCT02432898 — intervention group
Intervention type: DEVICE
Intervention: 3D OCT-1
Description: Spectral Domain OCT Device
Study NCT02432898 — intervention group
Intervention type: DEVICE
Intervention: 3D OCT-2000
Description: Spectral Domain OCT Device
Study NCT02432898 — intervention group
Intervention type: DEVICE
Intervention: DRI OCT-1
Description: Swept Source OCT Device
Study NCT02432898 — intervention group
Intervention type: DEVICE
Intervention: NW-300
Description: Fundus Camera
Study NCT02432898 — intervention group
Intervention type: DEVICE
Intervention: CT-1P
Description: Tonometry
Study NCT02432898 — intervention group
Intervention type: DEVICE
Intervention: TRK-2P
Description: Tonometry, Corneal Topography
Study NCT02432898 — intervention group
Intervention type: DEVICE
Intervention: SP-1P
Description: Specular Microscopy
Study NCT02432898 — intervention group
Intervention type: DEVICE
Intervention: SL-D701
Description: Slit Lamp Imaging
Study NCT04322097 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mandibular advancement
Description: Outcome variables will be assess with and without mandibular advancement
Study NCT04322097 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Postural maneuvers
Description: Outcome variables will be measured with and without postural maneuvers
Study NCT04322097 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Digital Morphometrics
Description: A digital camera with laser pointers will be used to capture a series of craniofacial photographs (frontal, profile and neck extended) and intra-oral photographs (junction of the hard and soft palate, airway, or base of tongue).
Study NCT04322097 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tongue Force Exercise
Description: The patient will place a small bulb behind their lower incisors and will press using their tongue as hard as possible for two seconds. This exercise will be repeated four times, with 30 seconds of rest in between each attempt. The patient will then be instructed to press and hold their tongue against the bulb as hard as possible for 35 seconds. This exercise will be repeated three times, with 2 minutes of rest in between each attempt.
Study NCT04322097 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic resonance imaging (MRI)
Description: The patient will undergo an MRI scan of the head and neck.
Study NCT04322097 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Polysomnography (PSG) - Split Night
Description: The patient will undergo a polysomnography (PSG). The PSG study will include monitoring of EEG, submental EMG, EOG, SpO2, tidal airflow, thoraco-abdominal efforts, and body position. The patient will spend half of the night at baseline (i.e. no intervention), and the second half with lingual muscle stimulation activated.
Study NCT02432898 — intervention group
Intervention type: DEVICE
Intervention: MC-4S
Description: Visual Acuity Testing
Study NCT01847768 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GMP-grade HRV-39
Description: Experimental rhinovirus infection: an FDA approved, GMP-grade HRV-39 stock (gift from Dr. Ronald B. Turner, University of Virginia), which has now been approved by Health Canada for human experimental use, will be used in this study.
Study NCT01847768 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GMP-grade HRV-39
Description: Experimental rhinovirus infection: an FDA approved, GMP-grade HRV-39 stock (gift from Dr. Ronald B. Turner, University of Virginia), which has now been approved by Health Canada for human experimental use, will be used in this study.
Study NCT01847768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar Lavage
Study NCT01847768 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoalveolar Lavage
Study NCT01847768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methacholine Inhalation Challenge
Description: The purpose of this test is to determine if lung airways narrow by more than 20%, which confirms an asthma diagnosis.
Study NCT01847768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methacholine Inhalation Challenge
Description: The purpose of this test is to determine if lung airways narrow by more than 20%, which confirms an asthma diagnosis.
Study NCT01847768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasal Lavage
Study NCT01847768 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Lavage
Study NCT01847768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasal Scrapings
Description: This process uses a rhinoprobe to gently scrape the mucosal lining of the nose
Study NCT01847768 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Scrapings
Description: This process uses a rhinoprobe to gently scrape the mucosal lining of the nose
Study NCT01847768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchial Brushings
Study NCT01847768 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchial Brushings
Study NCT01847768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung Mucosal Biopsy
Study NCT01847768 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lung Mucosal Biopsy
Study NCT01847768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allergen Skin Prick Testing
Description: For the purposes of this study, allergy skin testing will be done with the following aero-allergens: cat epidermis, dog epidermis, horse, grass mix, tree mix, weed mix, ragweed and house dust mite, along with a histamine positive control and a buffer \& glycerol negative control.
Study NCT01847768 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allergen Skin Prick Testing
Description: For the purposes of this study, allergy skin testing will be done with the following aero-allergens: cat epidermis, dog epidermis, horse, grass mix, tree mix, weed mix, ragweed and house dust mite, along with a histamine positive control and a buffer \& glycerol negative control.
Study NCT01847768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Venipuncture
Description: Peripheral blood for assessment of neutralizing antibodies to HRV-39
Study NCT01847768 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Venipuncture
Description: Peripheral blood for assessment of neutralizing antibodies to HRV-39
Study NCT01847768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: A small flexible tube the size of a pencil, with a video-camera built into the tip (called a bronchoscope), will be inserted through the nose or mouth and down into the lungs.
Study NCT01847768 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopy
Description: A small flexible tube the size of a pencil, with a video-camera built into the tip (called a bronchoscope), will be inserted through the nose or mouth and down into the lungs.
Study NCT01847768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spirometry
Study NCT01847768 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spirometry
Study NCT03773471 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Health App
Description: ArthritisPower App
Study NCT03976362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo to olaparib, tablets
Study NCT02226601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: 3 days perioperative Aprepitant once a day
Study NCT03636243 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Vascularly biological assessment
Description: 22.5 ml of blood will be collected at day -15, month 3 and month 12.
Study NCT03636243 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Analysis of vasomotor endothelial function
Description: Evaluation of the peripheral endothelial function by digital tonometry using the 'EndoPATTM2000' system \[Itamar Medical Ltd., Caeserea, Israel\] before and after induction of post occlusive reactive hyperemia at day -15, month 3 and month 12.
Study NCT02226601 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 days perioperative Placebot once a day
Study NCT04472195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation Airway Coaching
Description: Airway coaching on laryngoscopy technique for intubation of neonates/infants within 1 hour of case utilizing RCDP simulation technique.
Study NCT03636243 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Analysis of arterial compliance
Description: Evaluation of the aortic pulse wave velocity in the aortofemoral segment or in the periphery (on the arm-ankle segment) by calculation of central aortic pressure (CAP) using the tonometric system 'Complior ™' \[Alam Medical, France\] at day -15, month 3 and month 12
Study NCT03636243 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Exploration of microcirculation
Description: The microcirculation exploration via analysis of the curves recorded by Laser Doppler at day -15, month 3 and month 12
Study NCT03636243 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Venous Doppler Ultrasound
Description: aneurysm screening at day -15, month 3 and month 12
Study NCT03636243 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Arterial pressure measurement
Description: measurement of the systolic pressure at the toe using the SysToe™ device, and measurement of systolic and diastolic blood pressure using the Dinamap™ device at day -15, month 3 and month 12
Study NCT03636243 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Intima-Media Thickness measurement
Description: Intima-Media Thickness measurement using an ultrasound machine at day -15, month 3 and month 12
Study NCT03440710 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BET
Description: Balloon Eustachian Tuboplasty
Study NCT03128021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram Pill
Description: Double-blinded, randomly assigned
Study NCT03128021 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Escitalopram Pill
Description: Double-blinded, randomly assigned
Study NCT03128021 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double-blinded, randomly assigned
Study NCT03440710 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: BET
Description: Balloon Eustachian Tuboplasty
Study NCT02584114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peak app for memory training
Study NCT03636243 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Exploration of neuropathy
Description: non-invasive measurement of sudomotor function by SUDOSCAN at day -15, month 3 and month 12
Study NCT04016207 — intervention group
Intervention type: DRUG
Intervention: Guanfacine
Description: regular treatment
Study NCT02764970 — intervention group
Intervention type: DRUG
Intervention: Ivabradine 7.5mg orally
Description: additive use to the standard medication with bisoprolol
Study NCT03170050 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YYD701-2
Description: HA Filler
Study NCT03170050 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane Perlane Lidocaine
Description: HA Filler
Study NCT01003366 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bevel direction during central venous catheterization
Description: approaching the IJV with the needle bevel facing down
Study NCT01003366 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bevel direction during central venous catheterization
Description: approaching the IJV with the needle bevel facing up
Study NCT02446106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soup with MSG
Description: 0.5% MSG + 0.48% salt
Study NCT02446106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control soup no MSG
Description: Negative control match for sodium (no MSG + 0.635% salt)
Study NCT04596488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz 400mg
Description: HIV-infected patients were treated with efavirenz 400mg combined with tenofovir 300mg and lamivudine 300mg.
Study NCT04047407 — intervention group
Intervention type: DEVICE
Intervention: Suprathreshold pain stimulation
Description: Suprathreshold pain stimulation will be applied in the infraspinatus muscle (point equidistant between the midpoint of the spine of the scapula, the inferior angle of the scapula and the midpoint of the medial border of the scapula) with a pressure algometer (Force Ten ™, Wagner Instruments, USA). Four suprathreshold pressure stimulations (pressure pain threshold + 20%, +30%, +40% and +50%) will be made for 60 seconds, with a minimum rest of 5 minutes between each stimulation.~The sequence of stimulation (ascending or descending) will be randomized.
Study NCT01798498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Princess® VOLUME
Study NCT04112810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildrakizumab
Description: 100 mg will be injected subcutaneously on Day -1, Day 28 ± 3, Day 112 ± 7, Day 196 ± 14, and Day 280 ± 14.
Study NCT02851134 — intervention group
Intervention type: GENETIC
Intervention: genetic analysis
Description: genetic (Whole Exome Sequencing )
Study NCT02851134 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood and stools samples
Description: biological collection
Study NCT02584114 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-memory training group
Study NCT03277105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dara SC
Description: Participants will receive a fixed dose of Dara SC as 1800 mg daratumumab with rHuPH20 2000 U/mL, once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study.
Study NCT03636243 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: level of physical activity
Description: pedometer collecting the number of steps during the four days before visits at day -15, month 3 and month 12
Study NCT03277105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dara SC
Description: Participants will receive a fixed dose of Dara SC as 1800 mg daratumumab with rHuPH20 2000 U/mL, once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study.
Study NCT03277105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dara IV
Description: Participants will receive Dara IV 16 mg/kg once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study.
Study NCT03636243 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: thoracic scanner
Description: non-injected thoracic scanner visit at month 3
Study NCT02349191 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Omental transposition for mild Alzheimers disease
Description: An omental pedicle is brought from the abdomen underneath the skin and sewn to the dura matter of the brain via a craniotomy.
Study NCT03526809 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scan and FDG-PET scan
Description: Scanning with MRI and FDG-PET
Study NCT01857388 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ParentCorps
Study NCT01671189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS Reminder Software Tool
Description: The 150 patients in the intervention arm of the study will receive SMS reminders regarding their upcoming appointments. Working in parallel with the SMMC electronic medical records system, the software tool will automate reminders that request text responses from patients to either confirm or request to reschedule their upcoming appointments. This bidirectional text messaging system would not interfere with the clinics' existing reminder protocol.
Study NCT01778881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage and stretching exercises
Description: The routine to be used in this group (stretching, massage, and diaphragmatic breathing).
Study NCT01778881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxation and imagination therapies
Description: The routines to be adopted will focus on progressive muscle relaxation associated to imagination and diaphragmatic breathing.
Study NCT01778881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dental treatment
Description: Restoring treatment will involve direct reconstruction of the anterior guides (incisive faces of the incisive and canine teeth) with resin.
Study NCT01778881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage, exercises, relaxation and imagination therapies
Description: The routine to be used in this group (stretching, massage, diaphragmatic breathing, progressive muscle relaxation and imagination therapies).
Study NCT01574157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium bicarbonate
Description: Participants will receive 0.5 meq of sodium bicarbonate per 1 kilogram of lean body weight daily. The total amount will be divided into twice daily doses.
Study NCT01574157 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive an identical number of placebo tablets had they been assigned to the intervention. Placebo will be divided into twice daily doses and receive this for six months.
Study NCT00457821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor 25 mg/75 mg
Description: 25 mg or 75 mg q12h for a total of 28 days (Part 1)
Study NCT00457821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor 75 mg/150 mg
Description: 75 mg or 150 mg q12h for a total of 28 days (Part 1)
Study NCT00457821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor 150 mg or 250 mg
Description: 150 mg or 250 mg of ivacaftor q12h for 28 days (Part 2)
Study NCT00457821 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given q12h for 28 days each in Part 1 and Part 2 of the study
Study NCT01666535 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Influenza vaccination
Study NCT02298179 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV F subunit 45 μg No adjuvant
Description: 2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
Study NCT02298179 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV F subunit 45 μg Aluminum hydroxide adjuvant
Description: 2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
Study NCT02298179 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV F subunit 45 μg MF59 adjuvant
Description: 2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
Study NCT02298179 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV F subunit 90 μg No adjuvant
Description: 2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.